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ABSTRACT 
Objective: To describe the incidence of three conditions of acute severe maternal morbidity 
in selected regions in nine European countries. 
Design: A population based questionnaire survey.  
Setting: 11 regions in nine countries of Europe. 
Population: All the pregnant women in each region who had delivered during the time period 
covered by the study. 
Methods: Standard definitions of three severe obstetric conditions, pre-eclampsia, postpartum 
haemorrhage and sepsis were established by a Steering Committee. A common questionnaire 
was used in each participating country. The incidence of the three obstetric conditions and 
characteristics of the study women were compared. 
Results: The study identified 1734 women with at least one of the three conditions, with 847 
experiencing severe haemorrhage, 793 experiencing severe pre-eclampsia and 142 
experiencing severe sepsis. There were wide variations in incidence of three conditions 
combined, ranging from 14.7 per thousand in deliveries in Brussels, Belgium to 6.0 per 
thousand in Upper Austria.  
Conclusions: It was possible to use standard definitions to identify and ascertain the 
incidence of three severe obstetric conditions at a regional level. The incidence of these severe 
obstetric conditions in general and severe haemorrhage varied significantly between countries. 
Overall, severe haemorrhage was the most common of the three conditions, followed closely 
by severe pre-eclampsia.  
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INTRODUCTION 
Recent research has suggested that severe maternal morbidity may be a better indicator of the 
quality and effectiveness of obstetric care than mortality alone (1-4). Many earlier studies 
were small and restricted to a single country. Most were based on hospital populations and in 
many, cases of severe morbidity were defined as women admitted to an intensive care unit 
(ICU) with data being collected in the ICU only. Doing this invalidates international 
comparison as a European survey showed that countries differ in the ways they organised 
intensive care (5). As a consequence of this, comparisons based on ICU admissions are likely 
to be unreliable. In addition some of the studies were small and their definitions of the clinical 
conditions were inconsistent. 
 
Severe haemorrhage, severe pre-eclampsia including HELLP syndrome and eclampsia and 
severe sepsis were the three complications most consistently reported in previous studies as 
causes of admission to intensive care (1,6-9). They were also with thromboembolic disease 
the leading causes of maternal mortality reported in national surveys (10-12) and are a 
significant public health problem, especially in developed countries. 
 
The European concerted actions on ‘MOthers Mortality and Severe morbidity’ (MOMS) 
aimed to overcome these problems by using common definitions and collecting population-
based data. The project had two parts, Survey A which collected and compared national data 
on maternal deaths (13) and Survey B which identified cases of severe morbidity in eleven 
regions within nine countries. This paper describes survey B. 
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METHODS 
 
Defining the conditions 
A steering committee of European clinicians and epidemiologists was set up in 1994. It met to 
establish the conditions to be studied and agreed on definitions for them. The criteria for these 
definitions, shown in Table 1, were that they should be mutually acceptable, applicable in 
practice and clinically based.  The diagnosis of severe pre-eclampsia was purely clinical. It 
was taken from the US National High Blood Pressure Education Program Working Group 
report on High Blood Pressure in pregnancy (14). The only modification was to exclude the 
three blood criteria relating to platelets, creatinine and hepatic enzymes. The steering 
committee produced its own definition of severe haemorrhage.  For sepsis, it adopted 
unchanged the definition produced by the American College of Chest Physicians / Society of 
Critical Care Medicine Consensus Conference (15). 
 
Populations covered 
Nine countries of the European Union and two countries outside the European Union, 
Hungary and Norway, participated. In most of the countries, data collection took place in just 
one region, but in France three regions were included and in Finland the whole country was 
covered. Data for Denmark and Spain were excluded from the analysis, because of 
incompleteness. The regions are listed in Table 2  
 
Inclusion criteria and data collection 
Data were collected about women who delivered after 24 completed weeks of gestation and 
experienced one or more of the three conditions being studied. 
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A data collection form was designed by the steering group. The data items included were the 
woman’s demographic details, her medical and obstetric history, her antenatal care during the 
index pregnancy, the stage of pregnancy at which one of the conditions first arose and the care 
given. Data were collected by specially trained researchers who visited each hospital in each 
region at two weekly intervals. The exception was in France where data were collected 
retrospectively from case notes. 
 
The women’s post codes were recorded to exclude those who lived outside the region, Data 
were collected over the years, 1995 to 1998, but the time periods covered varied from country 
to country, as Table 2 shows. To ensure that no deaths associated with the conditions studied 
were excluded, data were also collected about all maternal deaths in each region. The 




Incidence rates were calculated for each condition separately as well as in terms of the 
numbers of women with one or more of the conditions. A woman with several conditions is 
counted separately within each condition. Therefore the numbers with each condition cannot 
be added to derive the total number of women. Ninety five per cent confidence intervals were 
constructed for the rates. Countries’ rates were compared using the chi-squared test. The 
Kruskal-Wallis H test was used to compare the distributions of women’s ages. 
 
The analyses were performed using the Statistical Package for the Social Sciences (SPSS) 
version 10.0 (16).  
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RESULTS 
 
The methods of ascertainment, the study period and the number of deliveries in each 
participating region are summarised in Table 2 and the incidence rates and 95 per cent 
incidences intervals are shown in Table 3. Overall 1,734 women with one or more of the 
specified conditions were identified in all the study regions combined. 
 
Severe haemorrhage was the most common of the three conditions with an incidence of 4.6 
per thousand, followed by severe pre-eclampsia with an incidence of 4.3 per thousand while 
severe sepsis was much less common with an incidence of 0.8 per thousand.  Among the 793 
women with severe pre-eclampsia there were 660 with diagnoses of pre-eclampsia, 53 with 
diagnoses of eclampsia and 123 with diagnoses of HELLP.  
 
There were wide variations in the incidence rate of the three conditions combined, ranging 
from 14.7 in Belgium, 14.3 in Finland and 11.8 in the United Kingdom to 6.0 in Austria and 
6.1 in Ireland. 
 
Among the 1734 women there were 84 fetal deaths. There were four maternal deaths, three 
amongst women with a diagnosis of haemorrhage including two from France and one from 
Italy, One death among the women with a diagnosis of severe pre-eclampsia was reported 
from France. A further five deaths were recorded in the former South East Region of the 
United Kingdom during the study period, but because of the constraints under which the 
Confidential Enquiry into Maternal Deaths in the United Kingdom operates, details about 
them were not made available to our study (17). Nevertheless, they were included in 
calculations, which gave a case fatality of 5.2 per thousand among 1739 women. 
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Data about the women’s age and parity and whether they were admitted to an intensive care 
unit are shown in Table 4. On average, the women in Hungary were younger than those in 
other countries and the percentages of women aged fewer than 35 were lowest in Norway and 
Hungary. There was also a significant difference between the percentages of primaparae. 
 
Marked differences were seen in the percentages of women admitted to an intensive care unit. 
About half the Austrian women and around a quarter of women in Belgium, France, Italy and 
the United Kingdom were admitted. 
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In its use of common definitions and methods of data collection on a population basis, this 
study was an advance on studies that used admission to an intensive care unit as a proxy 
measure of acute severe maternal morbidity. This is not a valid basis for an international study 
as the availability and definition of intensive care units varies between countries and from 
place to place within countries as do the admission criteria. For example, in some Dutch 
hospitals, some intensive care, such as applying capillary wedge pressure with the Swanz-
Cranz catheter is undertaken within obstetric units. In addition, pilot studies in Brussels 
suggested that the threshold for transfer to intensive care units might vary according to the 
workload on the labour ward on the day concerned. 
The conditions were chosen firstly because they are leading causes of maternal mortality and 
secondly because they can be diagnosed without sophisticated equipment. Pulmonary 
embolism was excluded for the second reason, despite the fact that it is the leading cause of 
maternal death in the United Kingdom (18) 
For the same reason, the definition of pre-eclampsia was restricted to clinical criteria, on the 
assumption that there might be differences in the availability of and accessibility to laboratory 
and imaging techniques. Despite its precise definition, sepsis may not have been fully 
ascertained. There is evidence that some cases occurred after the woman had been discharged 
from hospital. If these cases were managed by primary care services, or in a hospital without a 
maternity unit, they may have been missed by the project researchers. 
 
Differences in incidence  
Overall differences between countries were dominated by differences in the incidence of 
haemorrhage. This ranged from 8.8 per thousand deliveries in Finland to 0.7 in Austria. 
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Possible explanations include differences in ascertainment, differences in the age distribution 
after women giving birth (17,19-21) and differences in the ways in which care is provided and 
in its quality (22-24).  
 
Observed differences should be interpreted with caution, however, given the small numbers of 
cases in some countries. Differences in ascertainment may also play a part. In France, the 
people who collected the data were qualified midwives and doctors but they collected data 
retrospectively from case notes and had not been involved in care for the women. This means 
that ascertainment was dependent on the completeness of the information in the notes. In 
other countries, data were collected on an ongoing basis, with the clinicians who had given 
care to the woman being asked to complete the study form at the same time as the case notes. 
Nevertheless the incidence rate of the three conditions combined was also low in Austria and 
Ireland, so differences in methodology do not necessary account for all the differences 
observed. 
Incidence rates may also reflect differences in clinical management. Haemorrhage is reported 
to be the leading cause of maternal death in Japan and Europe as a whole and the third most 
common cause in the United States (25-29). Active management of the third stage may 
decrease the incidence of haemorrhage (30-31). This approach is commonly advocated in the 
United Kingdom, but a survey of maternity units conducted in 2000-2001 showed 
considerable differences in practice between units (32).  
 
In our study, the countries with the highest incidence of morbidity were not necessarily those 
with the highest maternal mortality. Nor was there any obvious ecological association 
between morbidity and some other factor on the lines of the well-recognised association 
between infant mortality and per capita income (33). The three countries with the highest 
reported incidence of morbidity associated with the three selected conditions were Belgium, 
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Finland and the United Kingdom. This could be because these countries had the most 
complete ascertainment. It could also be that maternal mortality is more closely associated 
with the quality of care provided than with the prevalence of morbidity (34-35). 
 
It would have been useful to have calculated age and parity specific rates or standardised 
incidence rates for age and parity. Unfortunately, the data required were not available for all 
women delivering in the study areas for the time periods when the studies were under way. 
The wide differences apparent in Table 4 in the percentages of older women and or 
primparous women among the cases of severe morbidity identified in the study, suggest that 
these could reflect differences in the childbearing populations in the regions studied. 
 
It is also likely that the choice of regions within countries may have contributed to the 
differences observed. For example Brussels and the former South East Thames region of 
England both include substantial inner city areas with high proportions of women from 
migrant and minority ethnic groups, while France chose three regions without major cities. 
 
Comparisons with other studies of maternal morbidity and the incidence of the conditions 
ascertained in our study are summarised in Table 5.  As can be seen, some were undertaken in 
the countries of Europe which took part in our collaboration and some in other developed 
countries (36-46). 
 
Is ‘near miss’ maternal morbidity a useful concept? 
A number of recent articles have explored the concept of ‘near miss’ maternal morbidity and 
proposed it as a useful tool for monitoring maternal health. (47). It is however a concept, 
which requires further calcification and definition before it can be used widely in comparative 
studies. In our study, it is likely that despite concerted unequivocal definitions, the differences 
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in rates observed between regions are partly related to ascertainment differences. This is most 
likely to be true for haemorrhage, where diagnosis is always difficult (48), but more detailed 
exanimation showed it can apply elsewhere (49). Difficulties with the concept of “near-miss” 
exist on many levels. On a purely semantic level, authors have yet to agree on a unique 
expression which would encompass these cases of severe morbidity.  Attempting to identify 
them in a Medline search, each of the expressions: “critical”, “catastrophic”, “life-
threatening”, “near-miss”, “severe” “emergency” and “intensive care” identified articles, 
which were not retrieved by any of the others. There may be further keywords that we have 
not identified.  This semantic problem is only the tip of the iceberg. Even if we could agree on 
a unique term to be used in all cases where the clinician believes life to be in danger, how 
reproducible would this concept be? Is there a need for a comprehensive list? By definition it 
is bound to exclude fatal condition. In addition to the subjectivity inherent in the formulation 
of such a list, identification cases would still be dependent on the nature and organisation of 
health care systems. In the same way as assessment of maternal deaths in the developing 
world is hampered by lack of good information systems, it might be difficult to assess a’ near 
miss’, even in the developed world if vital information is not recorded in clinical notes or if 
the notes were lost. 
As, maternal mortality is a rare event in developed countries, moves towards monitoring 
maternal morbidity may be desirable. Potential indicators cover a wide spectrum of subjective 
measures ranging from well being (50), long-term disability, mental ill health, to severe 
physical morbidity.  Il has been suggested that a conceptual framework for ‘near miss’ 
maternal morbidity should include a complex set of items, including clinically defined 
conditions such as severe pre-eclampsia, events such as seizures, and procedures such as 
ventilation (47). This approach was, in effect, the one the steering committee had developed 
early on in the MOMS study, although it had not formally acknowledged the need for a mixed 
MOMS-B-BJOG 
Zhang Page 12 31/07/2012 
set of outcome measures. We therefore believe that the MOMS study is an exploratory study 
in this direction. Further work will be necessary to agree on an operational indicator for 
severe disease in pregnancy.  Further exploration of the validity of such a tool could include 
case control studies. Meanwhile population based epidemiological descriptions of severe 
maternal morbidity are appearing (17, 51).  
CONCLUSIONS 
 
 By using standardised definitions and a population-based approach, we have demonstrated 
that conditions associated with acute severe maternal morbidity are not rare. Severe 
haemorrhage was the most common of the three conditions we studied, but its incidence 
varied widely between European countries. 
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Table 1. Definition of selected conditions of severe maternal morbidity 
Severe pre eclampsia14 is pre eclampsia, defined as hypertension  
greater than 140/90 mm Hg or blood pressure increases of 30mm Hg systolic or 15mm Hg 
diastolic and proteinuria  greater than 0.3g 
complicated by one or more of the following: 
Hypertension greater than 160/110 mm H 
Proteinuria greater than 2.0 g/24h or +++on dipstick 
Oliguria < 60 ml for 2 successive hours or < 500 ml/24h 
Spigastric or liver pain 
Headache and blurred vision 
Pulmonary oedema 
 
Eclampsia is defined as any fitting in pregnancy, excluding fitting clearly related to known epilepsia. 
HELLP is defined as thrombocytopenia and hemolysis and hepatic cytolysis 
(Haemolysis, Elevated Liver,   
enzymes and Low Platelets).  Low platelets count below 100 × 109/l  
    and bilirubin ≥ 1.0 mg/dl  or 17.1 micromoles/l 
(haptoglobin ≤ 50 mg or schizocytes + ( if available)) 
and Elevated aspartate aminotransferase ≥ 70 U/l or  
elevated γ-glutamyltransferase ≥ 70 U/l 
Severe haemorrhage is limited to those occurring at the time of pregnancy outcome, including birth, abortion, 
caesarean, ectopic pregnancy.  
Severe haemorrhage is: 
     blood loss ≥ 1500 ml if measured 
or blood loss requiring plasma expanders and /or blood 2.500 ml in 24 hours or the same expressed in packed cells 
    or blood loss resulting in death 
 
Sepsis15 is limited to sepsis at the time of pregnancy outcome such as birth or abortion etc. Sepsis is a 
systemic inflammatory response to infection. There must coexist: 
    A. Infection such as bacteraemia, endometritis 
    B: Two or more of the following:  
Temperature greater than 38ºC or <36ºC 
     Heart rate greater than 90 beats/minute 
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     Respiratory rate greater than 20/min or PaCO2 <32 mmHg 
     White cell count greater than 17×109/l or < 4×109/l  
       or greater than 10% immature forms. 
 
 
 
 
